Table 10.

Studies on AOSD patients treated with interleukin-1 (IL-1) inhibitors published in the past.

	Lequerré et al., 2008	Laskari et al., 2011	Nordström et al., 2012	Giampietro et al., 2013	Gerfaud-Valentin et al., 2014b	Cavalli et al., 2015	Ortiz-Sanjuán et al., 2015	Rossi-Semerano et al., 2015
N° patients	15	25	12	28	6	20	41	35
N° patients Complete response (Remission∗)	11 (73.3%)	20 (80%)	6 (50%)	15 (53.5%)	5 (83.3%)	14 (70%)	14 (34.1%)	16 (45.7%)
N° patients Partial response∗∗	2 (13.3%)	4 (16%)	N/A	4 (14.2%)	0	2 (10%)	14 (34.1%)	–
N° patients Not effective∗∗∗	2 (13.3%)	1 (4%)	1	6 (21.4%)	1 (16.6%)	4 (20%)	7 (17.07%)	14 (40%)
Discontinued for reasons other than remission/AE	–	–	–	1 (3.5%) (pregnancy)	–	–	1 (2.4%) (pregnancy)	2 (5.7%) (at patient’s request)
Steroid dosages reduced	Yes	Yes	Yes	Yes	Yes	Yes	Yes	N/A
AE	2 (13.3%) Cutaneous reactions	3 (12%) Cutaneous reactions	11 (91.6%) Cutaneous reactions	2 (7.1%) Cutaneous reactions	0	2 (10%) Cutaneous reactions	8 (19.5%) Cutaneous reactions	3 (8.5%) Infections (pneumonia, 1 VZV reactivation, MAS and infection)
		7 (28%) Infections (2 RTI, 3 UTI, 1 GE, 1 tissue abscess)				2 (10%) VZV Reactivation	4 (9.7%) Infections (1 osteomyelitis, 1 RTI, 2 UTI, 1 VZV reactivation) 1 (2.4%) Leukopenia 1 (2.4%) myopahy

The times therapy efficacy were evaluated were different in the various studies. ^∗Remission: no fever (<37°C), no increase in inflammatory markers (ESR, CRP or ferritin), no tender or swollen joints. ^∗∗Partial response: clinical improvement without complete symptom improvement or complete normalization of inflammatory markers. ^∗∗∗Not effective: AOSD symptoms were unmodified during ANA treatment, including primary or secondary failure. RTI = respiratory tract infection; UTI, urinary tract infection; GE, gastroenteritis; VZV, varicella zoster virus; MAS, macrophage activation syndrome.